Human umbilical cord mesenchymal stem cell therapy on neuromyelitis optica

Current Neurovascular Research

Volumn 9, Issue 4, 2012, Pages 250-255

  Lu, Zhengjuan ^a,b   Ye, Dan ^a,b   Qian, Lai ^a,b   Zhu, Lin ^a,b   Wang, Chong ^a,b   Guan, Dening ^a,b   Zhang, Xiaoguang ^c   Xu, Yun ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c Jiangsu Provincial Stem Cell Engineering Research Center   (China)

Author keywords

B cells; Human umbilical cord derived mesenchymal stem cells; Immunosuppressive; Neuromyelitis optica; Safety; Therapy

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT DURATION; UMBILICAL CORD MESENCHYMAL STEM CELL TRANSPLANTATION;

EID: 84870475441     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720212803530708     Document Type: Article

References (27)

1. Albutt T. On the ophthalmoscopic signs of spinal disease. Lancet 1870;1:76-8.
2. Bichuetti DB, Oliveira EM, Souza NA, Rivero RLM, Gabbai AA. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler 2009;15:613-9.
3. Rivera JF, Kurtzke JF, Booth VJ, Corona T. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008;255:710-5.
4. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-27. (Pubitemid 37443332)
5. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14. (Pubitemid 29442132)
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12. (Pubitemid 39626806)
7. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2005;7:173-82. (Pubitemid 40894929)
8. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008;35:172-4.
9. Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 2010;227(1-2):185-9.
10. Rice CM, Mallam EA, Whone AL, et al. Safey and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 2010;87(6):679-85.
11. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology 2010;67(10):1187-94.
12. Juan Xu, Bingxin Ji, Li Su, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol 2001;90:343-8.
13. Alp Can, Sercin Karahuseyinoglu. Concise Review: Human Umbilical Cord Stroma with Regard to the Source of Fetus-Derived Stem Cells. Stem Cells 2007;25:2886-95. (Pubitemid 350127873)
14. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485.
15. Lanza C, Morando S, Voci A, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. Journal of Neurochemistry 2009;110(5):1674-84.
16. Fan CG, Zhang QJ, Zhou JR. Therapeutic Potentials of Mesenchymal Stem Cells Derived from Human Umbilical Cord. Stem Cell Rev and Rep 2011;7:195-207.
17. Malgieri A, Kantzari E, Patrizia M, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010;3(4):248-69.
18. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890.
19. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389.
20. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722.
21. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis & Rheumatism Arthritis Rheum 2010;62:2467-75.
22. Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011;4(2):111-21.
23. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-9. (Pubitemid 46592781)
24. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
25. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-77. (Pubitemid 41186945)
26. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-8. (Pubitemid 44036298)
27. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology 2008;4:557-67.